Vice Provost and Dean of Research
Showing 491-500 of 2,475 Results
-
Atman Desai, MD
Clinical Professor, Neurosurgery
Current Research and Scholarly InterestsThe Stanford Spine Artificial Intelligence Laboratory develops data-driven technologies to improve diagnosis, surgical planning, and outcomes in spine care. Our research spans predictive modeling, computational imaging, spinal oncology, digital surgery, and real-world functional assessment using wearables. By integrating clinical, imaging, and functional data at scale, we aim to deliver clinically meaningful, patient-centered innovations for complex spinal disease.
-
Manisha Desai (She/Her/Hers)
Kim and Ping Li Professor, Professor (Research) of Medicine (Quantitative Sciences Unit), of Biomedical Data Science and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Desai is the Director of the Quantitative Sciences Unit. She is interested in the application of biostatistical methods to all areas of medicine including oncology, nephrology, and endocrinology. She works on methods for the analysis of epidemiologic studies, clinical trials, and studies with missing observations.
-
Tushar Desai
Professor of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsBasic and translational research in lung stem cell biology, cancer, pulmonary fibrosis, COPD, and acute lung injury/ARDS. Upper airway stem cell CRISPR gene correction followed by autologous stem cell transplantation to treat Cystic fibrosis. Using lung organoids and precision cut lung slice cultures of mouse and human lungs to study molecular regulation of lung stem cells. Using transgenic mice to visualize Wnt protein transmission from niche cell to stem cell in vivo.
-
Joseph M. DeSimone
Sanjiv Sam Gambhir Professor of Translational Medicine, Professor of Chemical Engineering and, by courtesy, of Chemistry, of Materials Science and Engineering, and of Operations, Information and Technology at the Graduate School of Business
BioJoseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with courtesy appointments in the Department of Chemistry and in Stanford’s Graduate School of Business.
The DeSimone laboratory's research efforts are focused on developing innovative, interdisciplinary solutions to complex problems centered around advanced polymer 3D fabrication methods. In Chemical Engineering and Materials Science, the lab is pursuing new capabilities in digital 3D printing, as well as the synthesis of new polymers for use in advanced additive technologies. In Translational Medicine, research is focused on exploiting 3D digital fabrication tools to engineer new vaccine platforms, enhanced drug delivery approaches, and improved medical devices for numerous conditions, with a current major focus in pediatrics. Complementing these research areas, the DeSimone group has a third focus in Entrepreneurship, Digital Transformation, and Manufacturing.
Before joining Stanford in 2020, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 - 2019) of the additive manufacturing company, Carbon. DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM.
In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He has received numerous other major awards in his career, including the U.S. Presidential Green Chemistry Challenge Award (1997); the American Chemical Society Award for Creative Invention (2005); the Lemelson-MIT Prize (2008); the NIH Director’s Pioneer Award (2009); the AAAS Mentor Award (2010); the Heinz Award for Technology, the Economy and Employment (2017); the Wilhelm Exner Medal (2019); the EY Entrepreneur of the Year Award (2019 U.S. Overall National Winner); and the Harvey Prize in Science and Technology (2020). He is one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech. -
Thomas Devereaux
Professor of Photon Science, of Materials Science and Engineering and Senior Fellow at the Precourt Institute for Energy
Current Research and Scholarly InterestsMy main research interests lie in the areas of theoretical condensed matter physics and computational physics. My research effort focuses on using the tools of computational physics to understand quantum materials. Fortunately, we are poised in an excellent position as the speed and cost of computers have allowed us to tackle heretofore unaddressed problems involving interacting systems. The goal of my research is to understand electron dynamics via a combination of analytical theory and numerical simulations to provide insight into materials of relevance to energy science. My group carries out numerical simulations on SIMES’ high-performance supercomputer and US and Canadian computational facilities. The specific focus of my group is the development of numerical methods and theories of photon-based spectroscopies of strongly correlated materials.
-
Renumathy Dhanasekaran
Assistant Professor of Medicine (Gastroenterology)
Current Research and Scholarly InterestsThe overall goal of my research is to understand the molecular pathogenesis of liver cancer and identify biologically relevant prognostic biomarkers and molecular targets for therapy in patients with hepatocellular carcinoma (HCC). My long-term objective is to improve the clinical outcome of patients with liver cancer.
